The recent news of an adverse reaction suffered by a participant in AstraZeneca’s Covid-19 vaccine candidate’s clinical trial demonstrated that getting an approved vaccine to market is no straight forward matter. What the unfortunate event also shows, is that the race to be first across the finish line with a viable solution is far from over.The field is still open, then, for vaccine specialist Vaxart (VXRT) to make its mark. The small cap is still far behind other major players in the development of its COVID-19 vaccine program, but following the publication of promising pre-clinical trial data, B Riley FBR …read more
Source:: Yahoo Finance